Optimer has signed a string of partnerships to commercialize the antibiotic around the world; the latest is with AstraZeneca, which will market the drug in South America, Central America, Mexico and the Caribbean.
Optimer Pharmaceuticals Inc. has signed several regional partners to commercialize its antibiotic Dificid (fidaxomicin) for Colstridium difficile infection in different parts of the world. The latest is AstraZeneca PLC, which will market the antibiotic in South America, including in Brazil, Central America, Mexico and the Caribbean in a deal announced Dec. 3.
AstraZeneca – one of a few big pharmas still investing in antibiotic drug development – has the infrastructure in place...
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.
